Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: valabrega g. Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023. Front Oncol. 2023. PMID: 37781174 Free PMC article.
Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.
Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, Redana S, Martinello R, Valabrega G, Aglietta M, Ponzone R, Montemurro F. Rossi V, et al. Among authors: valabrega g. Oncologist. 2012;17(11):1418-25. doi: 10.1634/theoncologist.2012-0194. Epub 2012 Sep 4. Oncologist. 2012. PMID: 22951668 Free PMC article.
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
Costamagna A, Rossi Sebastiano M, Natalini D, Simoni M, Valabrega G, Defilippi P, Visentin S, Ermondi G, Turco E, Caron G, Cabodi S. Costamagna A, et al. Among authors: valabrega g. Sci Rep. 2019 Feb 28;9(1):3089. doi: 10.1038/s41598-019-39510-w. Sci Rep. 2019. PMID: 30816273 Free PMC article.
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
Montemurro F, Redana S, Valabrega G, Martinello R, Aglietta M, Palmiero R. Montemurro F, et al. Among authors: valabrega g. J Clin Oncol. 2008 Apr 20;26(12):2052-3; author reply 2053-4. doi: 10.1200/JCO.2007.15.5044. J Clin Oncol. 2008. PMID: 18421060 No abstract available.
125 results